Results 1 to 10 of about 35,682 (244)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]

Endocrine and Metabolic Science
Chronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe, Arden B. Piepho, Chetan K. Gomatam, Peyton Debell, Megan N. Ballinger, Jill A. Rafael-Fortney   +5 more
doaj   +2 more sources

Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines [PDF]

Biomolecules
Through the mineralocorticoid receptor, aldosterone controls extracellular volume and arterial blood pressure by stimulating Na+ absorption and K+ secretion in epithelial cells of the kidney, colon, and several glands.
Elena Kohm, Martina Feger, Michael Föller   +2 more
doaj   +2 more sources

Chemerin Activation of Toll‐Like Receptor 4 Drives Mineralocorticoid Receptor–Mediated Aortic Valve Remodeling in Chronic Kidney Disease [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Aortic stenosis is the most common valvular heart disease, and its progression is accelerated in chronic kidney disease (CKD), where multiple circulating abnormalities worsen its pathophysiology.
Tania Sánchez‐Bayuela, Matthieu Soulié, Mattie Garaikoetxea, Amaya Fernández‐Celis, Natalia López‐Andrés, Frédéric Jaisser   +5 more
doaj   +2 more sources

Use of nonsteroidal mineralocorticoid receptor antagonist in chronic kidney disease: A case report of a patient with Fabry disease in his mid-20s [PDF]

Journal of International Medical Research
Fabry disease is a rare X-linked lysosomal storage disorder caused by a defect in glycosphingolipid metabolism, which leads to the accumulation of globotriaosylceramide (Gb3) in various cell types.
Guan-Qiang Tian, Ping Yang, Zu-Chun Liao, Wen Xiao, Jun Li, Bin Song   +5 more
doaj   +2 more sources

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mineralocorticoid receptor (MR) induces cardiac inflammation cooperatively with nuclear factor‐κB and signal transducer and activator of transcription 3 (STAT3); MR blockers exert anti‐inflammatory effects.
Naoto Kuyama, Satoshi Araki, Koichi Kaikita, Nobuhiro Nakanishi, Naoya Nakashima, Shinsuke Hanatani, Yuichiro Arima, Masahiro Yamamoto, Taishi Nakamura, Eiichiro Yamamoto, Kenichi Matsushita, Kunihiko Matsui, Kenichi Tsujita   +12 more
doaj   +2 more sources

Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post‐Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden.
Sina Danesh, Fazal Khan, Trevor Chopko, Aurora Lee, Ran Huo, Shuyang Lu, Vincy Tam, Wenbin Gao, Austin Todd, Joseph J. Maleszewski, Francis D. Pagani, Hartzell Schaff, Y. Eugene Chen, Paul A. Friedman, Hakan Oral, Marco Metra, Bertram Pitt, Ienglam Lei, Paul C. Tang   +18 more
doaj   +2 more sources

Administration of finerenone in chronic kidney disease [PDF]

Journal of Nephropathology, 2023
Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients.
Mohsen Akhavan Sepahi, Elham Emami, Akshaya Ann Joseph, Shakiba Hassanzadeh, Mohammad Reza Razavi   +4 more
doaj   +1 more source

Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension

Pulmonary Circulation, 2021
Abnormalities that characterize pulmonary arterial hypertension include impairment in the structure and function of pulmonary vascular endothelial and smooth muscle cells.
Divya P. Menon, Guanming Qi, Seung K. Kim, M. Elizabeth Moss, Krishna C. Penumatsa, Rod R. Warburton, Deniz Toksoz, Jamie Wilson, Nicholas S. Hill, Iris Z. Jaffe, Ioana R. Preston   +10 more
doaj   +1 more source

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
Mohamad El Wardani, Marc D. de Smet
doaj   +1 more source

Role of spironolactone in patients with resistant hypertension: A narrative review

Heart India, 2021
Treatment-resistant hypertension (RH) is defined as uncontrolled blood pressure (BP) despite use of at least three different antihypertensive agents (including angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, calcium channel ...
Geeta Sheth, Kavita Joshi
doaj   +1 more source